TF and cancer: This method requires the external addition of TF and phospholipids for coagulation initiation in the absence of TF-expressing cells, while our adaptation relies on the presence of endogenous TF, most likely present on spheroid-derived EVs or HUVECs inside the cancer-on-a-chip (as a result of tumor cell-derived proinflammatory cytokines) [19,23].